Skip to content

house · Committee report

H. Rept. 119-705

DESTRUCTION OF HAZARDOUS IMPORTS ACT

2026-06-18

Committees

Associated legislation

Text

Purpose and Summary

H.R. 2715 authorizes the Food and Drug Administration (FDA) to require that the owner or consignee of an FDA-regulated article that is subject to a destruction order to destroy such article, without an opportunity to export. Additionally, it would amend the Federal Food, Drug, and Cosmetic Act (FD&C Act) to prohibit the unauthorized movement of articles subject to a destruction order.

Background and Need for Legislation

Congress grants the FDA authority over certain imported products the FD&C Act.\1\ Specifically, sections 536 and 801 grant the FDA authority to determine whether FDA-regulated products may be offered for import into the United States and to refuse entry to articles that are contaminated, misbranded, or otherwise prohibited from being introduced into interstate commerce. --------------------------------------------------------------------------- \1\Food and Drug Administration (FDA), Import Basics (Nov. 25, 2025), https://www.fda.gov/industry/import-program/import-basics. --------------------------------------------------------------------------- Under current law, importers of commercial shipments that are refused entry by FDA have the option to either destroy or export the shipment, regardless of the public health risk posed by the product.\2\ However, FDA has observed entities engaging in ``port-shopping,'' a tactic whereby importers attempt to reimport refused entries back into the U.S. through a different port of entry.\3\ --------------------------------------------------------------------------- \2\Id. \3\Southern Shrimp Alliance, Destruction of Hazardous Imports Act Advances to Floor from House Energy and Commerce Committee (May 22, 2026), https://shrimpalliance.com/destruction-of-hazardous-imports-act- advances-to-floor-from-house-energy-and-commerce-committee/. --------------------------------------------------------------------------- The agency has sought the legislative authority to address this gap in its enforcement authority.\4\ FDA included this proposal in the most recent congressional justification for the FY 2027 budget request, citing risks from shipments previously offered for import, including food contaminated with Salmonella and Listeria, unapproved carcinogenic animal drugs, tainted human drugs, such as methanol-based hand sanitizers, and misbranded or contaminated medical devices, such as contact lenses, COVID-19 test kits, and personal protective equipment.\5\ --------------------------------------------------------------------------- \4\FDA, Executive Summary of FY 2023 FDA Legislative Proposals, Authority to Require Destruction of Imported Products that Pose a Significant Public Health Risk at 2 (Mar. 9, 2023), https:// www.fda.gov/media/157194/download?attachment; see also FDA, Executive Summary of FY 2024 FDA Legislative Proposals, Authority to Require Destruction of Imported Goods that Present a Significant Public Health Concern at 5 (Mar. 9, 2024), https://www.fda.gov/media/166049/ download?attachment; see also FDA, FY 2025 FDA Legislative Proposals, Require Destruction of Imported Products that Pose a Significant Health Risk at 6 (Mar. 30, 2025), https://www.fda.gov/media/176924/ download?attachment; see also FDA, Summary of FY 2026 Legislative Proposals, Require Destruction of Imported Products that Pose a Significant Public Health Risk at 3 (Apr. 29, 2026), https:// www.fda.gov/media/187068/download?attachment. \5\FDA, Fiscal Year 2027 Justification of Estimates for Appropriations Committees, Require Destruction of Imported Products that Pose a Significant Public Health Risk at 18 (Apr. 3, 2026), https://www.fda.gov/media/191778/download. --------------------------------------------------------------------------- H.R. 2715 aims to address risks posed by illicit and violative products by providing FDA the authority to require an importer to destroy any FDA-regulated product refused entry into the U.S. that presents a significant public health concern and require that importers to cover the costs of associated storage and destruction. The legislation would also authorize FDA to prohibit the movement of shipments labeled as contaminated, mislabeled, or otherwise hazardous to public health.

Committee Action

On March 26, 2026, the Subcommittee on Health held a legislative hearing on H.R. 2715. The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC; K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners; Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America; Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill; and, Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health. On May 13, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 2715, as amended, to the full Committee by a voice vote. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 2715, as amended, favorably reported to the House by a record vote of 43 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held hearings and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 2715 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to provide the FDA authority to require importers to destroy FDA-regulated products refused entry into the U.S. that pose public health concerns. The bill also prohibits the unauthorized movement of items the secretary has designated for destruction. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 2715 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearings were used to develop or consider H.R. 2715: On February 6, 2025, the Subcommittee on Health held a hearing on H.R. 2715. The title of the hearing was ``Combating Existing and Emerging Illicit Drug Threats.'' The Subcommittee received testimony from: Sheriff Michael Bouchard, Vice President of Government Affairs, Major County Sheriffs Association; Raymond Cullen, Family Advocate; Timothy Westlake, MD, FFSMB, FACEP, Emergency Medicine Physician, ProHealth Care Oconomowoc Memorial Hospital; Regina LaBelle, JD, Professor and Director, Master of Science in Addiction Policy and Practice, Georgetown University; and, Deepa Camenga, MD, MHS, FAACP, Chair, Committee on Substance Use and Prevention, American Academy of Pediatrics. On March 26, 2026, the Subcommittee on Health held a legislative hearing on H.R. 2715. The title of the hearing was ``Policies to Protect our Communities from Illicit Drug Threats.'' The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC; K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners; Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America; Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill; and, Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 2715 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Destruction of Hazardous Imports Act.'' Section 2. Destruction of certain refused articles Section 2 amends section 801 of the FD&C Act to provide FDA the authority to require that the owner or consignee of a refused entry that is deemed by the Secretary of Health and Human Services to present a significant public health concern to cover the cost of storage and destruction of such article. Additionally, it provides for due process to the owner or consignee of an article subject to a destruction order, which shall include notice and an opportunity to appear before the Secretary to testify on the destruction order. In addition to prohibiting the act of introducing an article subject to a destruction order into interstate commerce, this section directs FDA to promulgate final regulations to implement the amendments made by this section. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (new matter is printed in italics and existing law in which no change is proposed is shown in roman): FEDERAL FOOD, DRUG, AND COSMETIC ACT * * * * * * * CHAPTER III--PROHIBITED ACTS AND PENALTIES prohibited acts Sec. 301. The following acts and the causing thereof are hereby prohibited: (a) The introduction or delivery for introduction into interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded. (b) The adulteration or misbranding of any food, drug, device, tobacco product, or cosmetic in interstate commerce. (c) The receipt in interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise. (d) The introduction or delivery for introduction into interstate commerce of any article in violation of section 404, 415, 505,, 564, or 607. (e) The refusal to permit access to or copying of any record as required by section 412, 414, 417(j), 416, 504, 564, 605,703, 704(a), 760, or 761; or the failure to establish or maintain any record, or make any report, required under section 412, 414(b), 417, 416, 504, 505 (i) or (k), 512(a)(4)(C), 512 (j), (l) or (m), 572(i), 515(f), 519, 564, 605,611, 760, 761, 909, or 920 or the refusal to permit access to or verification or copying of any such required record; or the violation of any recordkeeping requirement under section 204 of the FDA Food Safety Modernization Act (except when such violation is committed by a farm). (f) The refusal to permit entry or inspection as authorized by section 704. (g) The manufacture within any Territory of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded. (h) The giving of a guaranty or undertaking referred to in section 303(c)(2), which guaranty or undertaking is false, except by a person who relied upon a guaranty or undertaking to the same effect signed by, and containing the name and address of, the person residing in the United States from whom he received in good faith the food, drug, device, tobacco product, or cosmetic; or the giving of a guaranty or undertaking referred to in section 303(c)(3), which guaranty or undertaking is false. (i)(1) Forging, counterfeiting, simulating, or falsely representing, or without proper authority using any mark, stamp, tag, label, or other identification device authorized or required by regulations promulgated under the provisions of section 404 or 721. (2) Making, selling, disposing of, or keeping in possession, control, or custody, or concealing any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to render such drugs a counterfeit drug. (3) The doing of any act which causes a drug to be a counterfeit drug, or the sale or dispensing, or the holding for sale or dispensing, of a counterfeit drug. (j) The using by any person to his own advantage, or revealing, other than to the Secretary or officers or employees of the Department, or to the courts when relevant in any judicial proceeding under this Act, any information acquired under authority of section 404, 409, 412, 414, 505, 510, 512, 513, 514, 515, 516, 518, 519, 520, 571, 572, 573, 704, 708, 721, 904, 905, 906, 907, 908, 909, or 920(b) concerning any method or process which as a trade secret is entitled to protection; or the violating of section 408(i)(2) or any regulation issued under that section.. This paragraph does not authorize the withholding of information from either House of Congress or from, to the extent of matter within its jurisdiction, any committee or subcommittee of such committee or any joint committee of Congress or any subcommittee of such joint committee. (k) The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling of, or the doing of any other act with respect to, a food, drug, device, tobacco product, or cosmetic, if such act is done while such article is held for sale (whether or not the first sale) after shipment in interstate commerce and results in such article being adulterated or misbranded. (m) The sale or offering for sale of colored oleomargarine or colored margarine, or the possession or serving of colored oleomargarine or colored margarine in violation of section 407(b) or 407(c). (n) The using, in labeling, advertising or other sales promotion of any reference to any report or analysis furnished in compliance with section 704. (o) In the case of a prescription drug distributed or offered for sale in interstate commerce, the failure of the manufacturer, packer, or distributor thereof to maintain for transmittal, or to transmit, to any practitioner licensed by applicable State law to administer such drug who makes written request for information as to such drug, true and correct copies of all printed matter which is required to be included in any package in which that drug is distributed or sold, or such other printed matter as is approved by the Secretary. Nothing in this paragraph shall be construed to exempt any person from any labeling requirement imposed by or under other provisions of this Act. (p) The failure to register in accordance with section 510 or 905, the failure to provide any information required by section 510(j), 510(k), 905(i), or 905(j), or the failure to provide a notice required by section 510(j)(2) or 905(i)(3). (q)(1) The failure or refusal-- (A) to comply with any requirement prescribed under section 518, 520(g), 903(b), 907, 908, or 915; (B) to furnish any notification or other material or information required by or under section 519, 520(g), 904, 909, or 920; or (C) to comply with a requirement under section 522 or 913. (2) With respect to any device or tobacco product, the submission of any report that is required by or under this Act that is false or misleading in any material respect. (3) The failure to comply with any requirement under section 524B(b)(2) (relating to ensuring device cybersecurity). (r) The movement of a device, drug, or tobacco product in violation of an order under section 304(g) or the removal or alteration of any mark or label required by the order to identify the device, drug, or tobacco product as detained. (s) The failure to provide the notice required by section 412(c) or 412(e), the failure to make the reports required by section 412(f)(1)(B), the failure to retain the records required by section 412(b)(4), or the failure to meet the requirements prescribed under section 412(f)(3). (t) The importation of a drug in violation of section 801(d)(1), the sale, purchase, or trade of a drug or drug sample or the offer to sell, purchase, or trade a drug or drug sample in violation of section 503(c), the sale, purchase, or trade of a coupon, the offer to sell, purchase, or trade such a coupon, or the counterfeiting of such a coupon in violation of section 503(c)(2), the distribution of a drug sample in violation of section 503(d) or the failure to otherwise comply with the requirements of section 503(d), the distribution of drugs in violation of section 503(e), failure to comply with the requirements under section 582, the failure to comply with the requirements under section 584, as applicable, or the failure to otherwise comply with the requirements of section 503(e). (u) The failure to comply with any requirements of the provisions of, or any regulations or orders of the Secretary, under section 512(a)(4)(A), 512(a)(4)(D), or 512(a)(5). (v) The introduction or delivery for introduction into interstate commerce of a dietary supplement that is unsafe under section 413. (w) The making of a knowingly false statement in any statement, certificate of analysis, record, or report required or requested under section 801(d)(3); the failure to submit a certificate of analysis as required under such section; the failure to maintain records or to submit records or reports as required by such section; the release into interstate commerce of any article or portion thereof imported into the United States under such section or any finished product made from such article or portion, except for export in accordance with section 801(e) or 802, or with section 351(h) of the Public Health Service Act; or the failure to so export or to destroy such an article or portions thereof, or such a finished product. (x) The falsification of a declaration of conformity submitted under section 514(c) or the failure or refusal to provide data or information requested by the Secretary under paragraph (3) of such section. (y) In the case of a drug, device, or food-- (1) the submission of a report or recommendation by a person accredited under section 523 that is false or misleading in any material respect; (2) the disclosure by a person accredited under section 523 of confidential commercial information or any trade secret without the express written consent of the person who submitted such information or secret to such person; or (3) the receipt by a person accredited under section 523 of a bribe in any form or the doing of any corrupt act by such person associated with a responsibility delegated to such person under this Act. (z) The dissemination of information in violation of section 551. (aa) The importation of a prescription drug in violation of section 804, the falsification of any record required to be maintained or provided to the Secretary under such section, or any other violation of regulations under such section. (bb) The transfer of an article of food in violation of an order under section 304(h), or the removal or alteration of any mark or label required by the order to identify the article as detained. (cc) The importing or offering for import into the United States of an article of food or a drug by, with the assistance of, or at the direction of, a person debarred from such activity under section 306(b)(3). (dd) The failure to register in accordance with section 415. (ee) The importing or offering for import into the United States of an article of food in violation of the requirements under section 801(m). (ff) The importing or offering for import into the United States of a drug or device with respect to which there is a failure to comply with a request of the Secretary to submit to the Secretary a statement under section 801(o). (gg) The knowing failure to comply with paragraph (7)(E) of section 704(g); the knowing inclusion by a person accredited under paragraph (2) of such section of false information in an inspection report under paragraph (7)(A) of such section; or the knowing failure of such a person to include material facts in such a report. (hh) The failure by a shipper, carrier by motor vehicle or rail vehicle, receiver, or any other person engaged in the transportation of food to comply with the sanitary transportation practices prescribed by the Secretary under section 416. (ii) The falsification of a report of a serious adverse event submitted to a responsible person (as defined under section 604,760, or 761) or the falsification of a serious adverse event report (as defined under section 760 or 761 or required under section 605(a)) submitted to the Secretary. (jj)(1) The failure to submit the certification required by section 402(j)(5)(B) of the Public Health Service Act, or knowingly submitting a false certification under such section. (2) The failure to submit clinical trial information required under subsection (j) of section 402 of the Public Health Service Act. (3) The submission of clinical trial information under subsection (j) of section 402 of the Public Health Service Act that is false or misleading in any particular under paragraph (5)(D) of such subsection (j). (kk) The dissemination of a television advertisement without complying with section 503B. (ll) The introduction or delivery for introduction into interstate commerce of any food to which has been added a drug approved under section 505, a biological product licensed under section 351 of the Public Health Service Act, or a drug or a biological product for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, unless-- (1) such drug or such biological product was marketed in food before any approval of the drug under section 505, before licensure of the biological product under such section 351, and before any substantial clinical investigations involving the drug or the biological product have been instituted; (2) the Secretary, in the Secretary's discretion, has issued a regulation, after notice and comment, approving the use of such drug or such biological product in the food; (3) the use of the drug or the biological product in the food is to enhance the safety of the food to which the drug or the biological product is added or applied and not to have independent biological or therapeutic effects on humans, and the use is in conformity with-- (A) a regulation issued under section 409 prescribing conditions of safe use in food; (B) a regulation listing or affirming conditions under which the use of the drug or the biological product in food is gener

Source: https://api.congress.gov/v3/committee-report/119/hrpt/705